Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Jörge E. Cortes et al.|New England Journal of Medicine|2019Cited by 464
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Oliver G. Ottmann|Blood|2007Cited by 249
Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic LeukemiaSusanne Badura, Oliver G. Ottmann|PLoS ONE|2013Cited by 70